Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine

A cell-based vaccine composed of autologous lymphoblastoid B cells activated against Epstein-Barr virus (EBV) in vitro with potential immunoprotective activity. Upon prophylactic administration, this vaccine may stimulate specific cytotoxic T-lymphocyte (CTL) and antibody responses against EBV-transformed B cells, thereby preventing an EBV-induced post-transplantation lymphoproliferative disorder.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous EBV-transformed B-lymphoblastoid cell vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search